Cardiac myxomas are known to be associated with cerebral aneurysms, however the mechanism of aneurysm formation is still debatable. Myxomatous tumor emboli to the vessel wall have been propounded as the plausible mechanism for aneurysm formation. Recent literature also implicates raised interleukin-6 (IL-6), secreted by atrial myxomas, in the genesis of aneurysms. We describe a patient who presented with mild persistent headache, later diagnosed to be harbouring multiple unruptured cerebral and systemic aneurysms. Our case highlights the importance of radiological modalities in timely diagnosis of myxoma with its cerebral and systemic embolic complications.
Introduction
Cardiac myxoma is a mesenchymal tumour and is the most common primary cardiac neoplasm [1] . As it usually arises in left atrium, systemic emboli from myxoma can spread to both cerebral and systemic vasculature, lead to ischemic, haemorrhagic complications and rarely aneurysms formation [2] [3] [4] . Aneurysms associated with myxomas are usually multiple, fusiform and peripheral [5, 6] . The embolization of tumor particles to vessel wall has been ascribed in weakening of subintimal tissue resulting in aneurysm formation [7] . Recent reports have also implicated the role of IL-6 in aneurysm genesis in patients harbouring atrial myxomas. IL-6 is a pro-inflammatory cytokine that has also been implicated in the development of cerebral aneurysms [8, 9] . Neurological manifestations in a patient presenting initially, may lead to discovery of primary tumor i.e. cardiac myxoma in the course of investigations and diagnosis, as in our case. We report a case of an adult male presenting with headache. Imaging and angiography revealed multiple cerebral & systemic aneurysms along with left atrial myxoma on echocardiography. 
. Surprisingly the patient had normal serum IL-6 levels (6 pg/ml), as opposed to many literature documentations.
Discussion
Cardiac myxoma is a mesenchymal tumor and accounts for half of all primary cardiac neoplasms, predominantly in (75%) left atrium [10] . Patients with cardiac myxoma usually presents with cardiac (60%), constitutional and embolic symptoms. Constitutional symptoms include anemia, weight loss, fever, elevated erythrocyte sedimentation rate, hypergammaglobulinemia and leukocytosis. Cardiac symptoms can be ascribed to impediment of myocardial function by left atrial tumor and comprise of dyspnea, palpitations and syncope [11] . Due to their proclivity for left atrium, systemic embolism is quite common. The neurological signs and symptoms in a patient of left atrial myxoma results from embolization, out of which cerebral ischemic & haemorrhagic changes, brain parenchymal metastasis and oncotic aneurysm formation are most common [12] . Ischemic infarcts due to vascular occlusion from embolised myxomatous particles have also been documented in various literature reports [13, 14] . First case of cerebral aneurysm associated with cardiac myxoma was reported by Stoane et al. [15] . Cerebral aneurysms can be diagnosed with CT and MRI angiographies, but catheter angiography is gold standard. Cerebral vascular aneurysms associated with myxoma are usually fusiform (may have saccular element) and peripherally located [16] .
Cerebral aneurysmal dilatations and vessel irregularities in patients of cardiac myxomas have been linked to neoplastic properties of a myxoma and embolism of tumor particles to vessel wall. The embolic oncotic particles deposit in the vessel wall, penetrate the vasa vasorum, causing weakening, ectasia and aneurysmal dilatation of vessel wall as has been demonstrated by various studies [17, 18] .
Many studies have supported the fact that atrial myxoma cells are capable of producing IL-6. IL-6 is a cytokine which causes differentiation & proliferation of cells along with overexpression of several proteolytic enzymes that degrade extracellular matrix (ECM), promoting fragmentation of tumor and acceleration of embolic event. Formation of cerebral aneurysm may be related to overproduction of IL-6 by tumor emboli causing degradation of ECM in cerebral vessels [19] [20] [21] .
Available literature suggests that the treatment of choice for atrial myxomas is surgical removal. Surgery should be conducted at the earliest so as to prevent the possible risk of further tumour embolism, cardiac valve obstruction and improving the cardiac function. Few literary evidences have also suggested presumably decreased number and size of aneurysms following myxoma resection. However, myxoma resection does not eliminate the risk of delayed aneurysm formation regardless the mechanism of development either by embolization or metastasis [22] . For this reason, followup monitoring for the development of aneurysms, using non-invasive imaging (MRI/MRA) is recommended after intervention for myxoma resection [23] . No definitive treatment has been advised, as of now, for aneurysms due to cardiac myxomas except for active observation.
Our patient has been under follow up of cardiac surgery department for atrial myxoma, under interventional neuroradiology and neurosurgery department for intracranial aneurysms. Up to recent OPD follow up, patient has been stable, been advised for myxoma resection and detailed about the prognosis. For size and numbers of intracranial aneurysms the patient is being followed up with MRA every 6 months under neurosurgery and neuro radiology department.
Multimodality radiological evaluation should be done in the patients presenting with multiple cerebral aneurysms, especially echocardiography to rule out the mycotic (valvular vegetations) or oncotic (atrial myxoma) etiologies and angiography (CTA, MRA or catheter angiography) to define the location and number of cerebro-systemic aneurysms.
Patients with multiple cerebral aneurysms should routinely be assessed for cardiac myxoma and vice-versa.
